К вопросу о преимуществах и недостатках цельноклеточных и бесклеточных коклюшных вакцин

04.04.2012

Литература

  1. ВОЗ. 1992. Серия технических докладов 800. 40-й доклад.
  2. Снегова Н.Ф. Безопасность и иммуногенность АКДС и инактивирован-ной полиомиелитной вакцин у ВИЧ-серопозитивных детей первого года жизни // Детские инфекции. 2005. Т. 4. № 4. С. 51 - 55.
  3. Снегова Н.Ф., Пушко Л.В., Илларионова Т.Ю. и др. Результаты применения комбинированной вакцины против дифтерии, коклюша, столбняка, полиомиелита и гемофильной инфекции типа В у детей с сопутствующими заболеваниями // Вопросы современной педиатрии. 2011. Т. 10. № 1. С. 115 - 118.
  4. Таточенко В.К., Намазова Л.С., Харит С.М. и др. Реактогенность и безопасность адсорбированных вакцин против коклюша, дифтерии и столбняка: результаты наблюдательного многоцентрового ис- следования // Вопросы современной педиатрии. 2006. T. 5. № 4. C. 32 - 38.
  5. Харит С.М., Воронина О.Л., Лакоткина Е.А. и др. Специфическая профилактика коклюша: проблемы и перспективы // Вопросы современной педиатрии. 2007. T. 6. № 2. С. 71 - 77.
  6. Харит С.М., Черняева Т.В., Начарова Е.П. и др. Ревакцинация детей в возрасте старше 1,5 года против дифтерии, коклюша, столбняка, полиомиелита и гемофильной инфекции // Вопросы современной педиатрии. 2009. Т. 8. № 6. С. 20 - 25.
  7. Чупринина Р.П., Перелыгина О.В., Алексеева И.А., Озерец-ковский Н.А. Сравнительная характеристика отечественных и зарубежных вакцин для профилактики коклюша, дифтерии и столбняка // Биопрепараты. 2006. № 4 (24). C. 27 - 30.
  8. Cherry J.D. «Pertussis vaccine encephalopathy»: it is time to recognize it as the myth that it is // JAMA. 1990. V. 263. P. 1679 - 1680.
  9. Cherry J., Gornbein J., Heininger U. et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses // Vaccine. 1998. V. 16 (20). P. 1901 - 1906.
  10. Cherry J., Heinnger U. Pertussis and other Bordetella infections / In: Feigin R., Cherry J., Demmler G. et al. / Textbook of Pediatric Infectious Diseases. 5th ed. - Philadelphia, PA: Saunders Co., 2004.
  11. Crowcroft N.S., Stein P, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? // Lancet Infect. Dis. 2003. V. 3. P 413 - 418.
  12. Decker M.D., Edwards K.M., Steinhoff M.C. et al. Comparison of 13 acel-lular pertussis vaccines: adverse reactions // Pediatrics (supplement). 1995. V. 96 (3). P. 557 - 566.
  13. Edmunds W.J., Brisson M., Melegaro A., Gay N.J. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales // Vaccine. 2002. V. 20. P 1316 - 1330.
  14. Edwards K.M. Pertussis vaccines / In: S. Plotkin, W. Orenstein, P. Offit (eds.). Vaccines, 5th ed. - Philadelphia: Saunders, 2008. P. 467 - 517.
  15. Edwards K.M., Decker M.D. Pertussis vaccines / In: S. Plotkin, W. Orenstein (eds.). Vaccines, 4th ed. - Philadelphia: Saunders, 2004. P. 471 - 528.
  16. Edwards K.M., Meade B.D., Decker M.D. et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response // Pediatrics. 1995. V. 96. P. 548 - 557.
  17. Gale J.L., Thapa P.B., Wassilak S.G. et al. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study // JAMA. 1994. V. 271. P. 37 - 41.
  18. Greco D., Salmaso S., Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis // New England Journal of Medicine. 1996. V. 334. P. 341 - 348.
  19. Griffin M.R., Ray W.A., Livengood J.R., Schaffner W. Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine // N. Engl. J. Med. 1988. V. 319. P. 618 - 623.
  20. Griffin M.R., Ray W.A., Mortimer E.A. et al. Risk of seizures and encephalopa-thy after immunization with the diphtheria-tetanus-pertussis vaccine // JAMA. 1990. V. 263. P. 1641 - 1645.
  21. Gustafsson L., Hallander H.O., Olin P. et al. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine // New England Journal of Medicine. 1996. V. 334. P 349 - 355.
  22. Gustafsson L., Hessel L., Storsaeter J., Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age // Pediatrics. 2006. V. 118. P. 978 - 984.
  23. Halperin S., Scheifele D., Barreto L. et al. Comparison of a fifth dose of a five-component acellular or a whole-cell pertussis vaccine in children four to six years of age // Pediatr. Infect. Dis. J. 1999. V. 18. P 772 - 779.
  24. Jefferson T. Systematic review of the effects of pertussis vaccines in children // Vaccine. 2003. V. 21. P. 2003 - 2014.
  25. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study // BMJ. 1988. V. 296. P. 612 - 614.
  26. Lambert H.J. Epidemiology of a small pertussis outbreak in Kent Country, Michigan // Public Health Rep. 1965. V. 80. P. 365 - 369.
  27. Langue J., Matisse N., Pacoret P. et al. Persistence of antibodies at 5 - 6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine: immunogenicity and tolerance of a second booster with a tetravalent acellular vaccine at 5 - 6 years of age // Vaccine. 2004. V. 22. P. 1406 - 1414.
  28. Lavigne M.V., Castro M., Mateo N. et al. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen // Microbes Infect. 2002. V. 4. P. 815 - 820.
  29. Mills K.H., Ryan M., McGuirk P. et al. The immunology of Bordetella pertussis infection // Biologicals. 1999. V. 27. P. 77.
  30. Moore D.L., Saux N.Le, Scheifele D., Halperin S.A. Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993 - 2002 // Pediatr. Infect. Dis. J. 2004. V. 23. P 568 - 571.
  31. Mortimer E.A., Cherry J.D. Pertussis (whooping cough) / In: A.A. Ger-shon, PJ. Hotez, S.L. Katz (eds.). Krugman's infectious diseases of children. - Philadelphia: Mosby, 2004. P 443 - 459.
  32. Number of Cases of Pertussis in California: Pertussis Summary Report 8-31-2010 California Department of Public Health. http://www.cdph.ca.gov/HEALTHINFO/DISCOND/Pages/Pertussis.aspx
  33. Olin P., Rasmussen F., Gustafsson L. et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine // Lancet. 1997. V. 350. P. 1569 - 1577.
  34. Pichichero M.E., Deloria M.A., Rennels M.B. et al. A safety and immuno-genicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15-to-20-month-old children // Pediatrics. 1997. V. 100. P. 772 - 788.
  35. Ranganathan S., Tasker R., Booy R. et al. Pertussis is increasing in unim-munized infants: is a change in policy needed? // Arch. Dis. Child. 1999. V. 80. P. 297 - 299.
  36. Ray P., Hayward J., Michelson D. et al. Encephalopathy after whole-cell pertussis and measles vaccination. Lack of evidence for a causal association in a retrospective case-control study // Pediatr. Infect. Dis. 2006. V. 25. P. 768 - 773.
  37. Salmaso S., Mastrantonio P., Tozzi A.E. et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience // Pediatrics. 2001. V. 108. P. E81.
  38. Senziler L.D., Halperin S.A., Spika J.S. et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents // Clin. Infect. Dis. 2001. V. 32. P. 1691 - 1697.
  39. Shields W.D., Nielsen C., Buch D. et al. Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study // J. Pediatr. 1988. V. 113. P 801 - 805.
  40. Simondon F., Preziosi M.P., Yam A. et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal // Vaccine. 1997. V. 15. P. 1606 - 1612.
  41. Solberg L. DPT immunization, visit to child health center and sudden infant death syndrome (SIDS). - Oslo: Health Council, 1985.
  42. Stehr K., Cherry J.D., Heininger U. et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acel-lular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine // Pediatrics. 1998. V. 101. P. 1 - 11.
  43. Storsaeter J., Hallander H., Farrington C.P. et al. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial // Vaccine. 1990. V. 8. P. 457 - 461.
  44. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Low levels of antiper-tussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis // Vaccine. 2003. V. 21 (25, 26). P. 3542 - 3549.
  45. Storsaeter J., Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance // Vaccine. 1992. V. 10. P. 142 - 144.
  46. Strathdee S.A., Loughlin A.M. Vaccines: past, present, and future / In: K.E. Nelson, C.M. Williams, N.M.H. Graham (eds.). Infectious disease epidemiology. - Gaithersburg (MD): Aspen Publishers, Inc., 2001. P. 255 - 280.
  47. Vickers D., Ross A.G., Mainar-Jaime R.C. et al. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children // CMAJ. 2006. V. 175. № 10. P. 1213 - 1217.
  48. Walker A.M., Jick H., Perera D.R. et al. Neurologic events following diphtheria-tetanus-pertussis immunization // Pediatrics. 1988. V. 81. P. 345 - 349.
  49. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination // Pediatric Infectious Disease Journal. 2005. V. 24 (Suppl. 5). P. S58 - S61.
  50. WHO. Department of Vaccines and Biologicals. Pertussis surveillance. A global meeting WHO/V&B/01.19. Geneva, 2001. http://whqlibdoc.who.int/hq/2001/WHO_V&B_01.19.pdf
  51. WHO. TRS 878. May 2011.
  52. WHO. Weekly epidemiological record // WHO. 2010. V. 85 (40). P. 385 - 400.
  53. WHO. World Health Report 2001. Mental health: new understanding, new hope. Annex 2. http://www.who.int/whr/2001/en/
  54. Zhang L., Prietsch S.O.M., Axelsson I., Halperin S.A. Acellular vaccines for preventing whooping cough in children // Cochrane Database of Systematic Reviews. 2008. V. 2. CD001478.